Clinical Trials

35 enrolled 12 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02639910 2021-12-20

COSMOS

24 enrolled 13 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02242045 2021-03-19

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

6 enrolled 14 charts

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT01088048 2021-03-18

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

241 enrolled 31 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT01569295 2020-03-10

Tugela

Phase 3 Completed

416 enrolled 16 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02603445 2020-02-24

Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL

20 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Mantle-Cell

NCT01282424 2019-07-11

DELTA

125 enrolled 25 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT01539512 2019-05-14

A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Phase 3 Completed

220 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03582098 2019-04-12

RETRO-idel

Completed

112 enrolled

Leukemia, B-Cell

NCT01306643 2018-11-19

Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma

Phase 1/2 Completed

18 enrolled 8 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT01393106 2018-11-19

Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma

25 enrolled 22 charts

Lymphoid

Hodgkin Disease

NCT00710528 2012-08-31

Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies